SCHEMBL760472

SCHEMBL760472

CC(C)c1ccc(OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.46
ALDH1A1 P00352 2/20 0.45
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
RAB9A P51151 1/20 0.39
IDO1 P14902 2/20 0.39
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
TYR P14679 2/20 0.38
PDE2A O00408 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 1/20 0.36
HIF1A Q16665 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19441283 0.90 ACACB (0.41) ACACBALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL18435569 0.85 MAPT (0.51) ACACBALDH1A1SMN1; SMN2MAPT
SCHEMBL9946029 0.84 ALDH1A1 (0.44) ACACBALDH1A1MEN1KMT2ARAB9A
SCHEMBL24158909 0.84 MCL1 (0.38) ACACBALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL15869220 0.83 ACACB (0.44) ACACBALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL15869207 0.83 ACACB (0.44) ACACBALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL196277 0.83 ACACB (0.44) ACACBALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL20643732 0.82 ALDH1A1 (0.42) ACACBALDH1A1MEN1KMT2ARAB9A
SCHEMBL11951591 0.82 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ARAB9AIDO1
SCHEMBL15521572 0.82 ACACB (0.44) ACACBALDH1A1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216526-A1 PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) 2024-07-04 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-20230152699-A1 FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-05-18 US disclosed
US-11649446-B2 Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids YALE UNIVERSITY (US) 2023-05-16 US disclosed
US-20210388016-A1 GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-12-16 US disclosed
WO-2021134951-A1 THERMOSETTING RESIN COMPOSITION AND PREPREG, LAMINATE AND PRINTED CIRCUIT BOARD USING SAME 广东生益科技股份有限公司 2021-07-08 WO disclosed
WO-2021134945-A1 THERMOSETTING RESIN COMPOSITION, AND PREPREG, LAMINATE AND PRINTED CIRCUIT BOARD USING SAME 广东生益科技股份有限公司 2021-07-08 WO disclosed
WO-2021133750-A1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 WO disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 US disclosed
US-10228621-B2 Underlayer film-forming composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2019-03-12 US disclosed
US-20090270412-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2009-10-29 US disclosed
US-20090227587-A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) WARNER-LAMBERT COMPANY LLC 2009-09-10 US disclosed
US-20090227587-A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) WARNER-LAMBERT COMPANY LLC 2009-09-10 US disclosed
US-20080070890-A1 Spirocyclic Azetidinone Compounds and Methods of Use Thereof SCHERING CORPORATION 2008-03-20 US disclosed
US-20080070889-A1 AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM SCHERING CORPORATION 2008-03-20 US disclosed
US-20070138139-A1 METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, ACID ETCHING RESISTANCE MATERIAL AND COPOLYMER ASAKAWA KOJI 2007-06-21 US disclosed
US-20070142592-A1 METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, ACID ETCHING RESISTANCE MATERIAL AND COPOLYMER ASAKAWA KOJI 2007-06-21 US disclosed
US-7208334-B2 Method of manufacturing semiconductor device, acid etching resistance material and copolymer KABUSHIKI KAISHA TOSHIBA (JP) 2007-04-24 US disclosed
US-7166603-B2 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
US-7166603-B2 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070890-A1 Spirocyclic Azetidinone Compounds and Methods of Use Thereof LIPC, ZDHHC20, PMP22 ACACB 40/4885ALDH1A1 258/4885SLC6A2 1860/4885
US-20090227587-A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) PIK3CA, PIK3CD, PIK3R5 ACACB 3866/4885ALDH1A1 2412/4885SLC6A2 3947/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ACACB 117/4885ALDH1A1 2858/4885SLC6A2 4436/4885
US-20210388016-A1 GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS SLC5A2, SLC5A1, UGGT1 ACACB 481/4885ALDH1A1 1242/4885SLC6A2 128/4885
US-20090270412-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C ACACB 4185/4885ALDH1A1 1514/4885SLC6A2 138/4885
US-20080070889-A1 AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM CYP46A1, OPRD1, OPRK1 ACACB 413/4885ALDH1A1 1024/4885SLC6A2 866/4885
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKZ, DGKK ACACB 3105/4885ALDH1A1 4765/4885SLC6A2 4806/4885
US-20240216526-A1 PREPARATION METHOD FOR DUAL-DRUG-LINKER OF ADC AND USE THEREOF SKP1, ADCY7, ERBB2 ACACB 2490/4885ALDH1A1 1714/4885SLC6A2 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.